Perfluorohexyloctane

Brand names: Miebo · Active ingredient: Perfluorohexyloctane

In short: MIEBO ®(perfluorohexyloctane ophthalmic solution) is indicated for the treatment of the signs and symptoms of dry eye disease (DED).

Forms & strengthsMIEBO (perfluorohexyloctane ophthalmic solution) is a sterile, clear and colorless ophthalmic solution containing 100% perfluorohexyloctane.
LabelBausch & Lomb Incorporated
Label updatedMar 12, 2026

What is Perfluorohexyloctane used for?

MIEBO

®(perfluorohexyloctane ophthalmic solution) is indicated for the treatment of the signs and symptoms of dry eye disease (DED).

Perfluorohexyloctane dosage

Instill one drop of MIEBO four times daily into affected eye(s).

Contact lenses should be removed prior to and for at least 30 minutes after the administration of MIEBO.

Step 1.Remove the cap from eye drop bottle.

Step 2.Holding the bottle upright, gently squeeze the bottle.

Step 3.While squeezing, turn the bottle upside down and release the pressure (drawing air into the bottle).

Step 4.Keeping the bottle upside down, place the bottle above your eye and squeeze it again to release a drop into your eye.

Repeat steps 1 - 4 for the second affected eye.

How to take Perfluorohexyloctane — instructions & advice from the label

Use with Contact Lenses

Advise patients that contact lenses should be removed prior to and for at least 30 minutes after administration of MIEBO.

Administration Instructions

Advise patients to instill one drop of MIEBO four times daily into each eye as depicted in the Administration Instructions

.

Distributed by:

Bausch & Lomb Americas Inc.

Bridgewater, NJ 08807 USA

Patented. See

https://patents.bausch.comfor US patent information.

MIEBO is a trademark of Bausch & Lomb Incorporated or its affiliates.

© 2025 Bausch & Lomb Incorporated or its affiliates

9805301

Warnings & precautions

Do not take this medicine if: MIEBO is contraindicated in patients with a history of hypersensitivity reaction to perfluorohexyloctane

.

MIEBO should not be administered while wearing contact lenses. Advise patients that contact lenses should be removed prior to and for at least 30 minutes after administration of MIEBO.

Perfluorohexyloctane side effects

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In patients with DED, 614 patients received at least one dose of MIEBO in two randomized controlled clinical trials across 68 sites in the United States. The most common ocular adverse reaction was blurred vision. Blurred vision and conjunctival redness were reported in 1-3% of individuals.

In four premarketing studies (three open-label [n=127], one randomized [n=24 treated with at least one dose of perfluorohexyloctane]) the most common adverse reaction was hypersensitivity.

About this medicine

MIEBO

®(perfluorohexyloctane ophthalmic solution) is a sterile, clear and colorless liquid containing 100% perfluorohexyloctane, for topical ophthalmic use.

The active ingredient is 1,1,1,2,2,3,3,4,4,5,5,6,6-tridecafluorotetradecane and is a semifluorinated alkane. It has a molecular formula of C

14H

17F

13and a molecular weight of 432.26 g/mol. The chemical structure is:

Perfluorohexyloctane is practically immiscible with water. It is miscible with ethanol and most

organic solvents. Each multiple-dose bottle contains 3 mL of perfluorohexyloctane, 1.338 g/mL as a clear and colorless liquid.

How it works: Perfluorohexyloctane, a semifluorinated alkane, contains 6 perfluorinated carbon atoms and 8 hydrogenated carbon atoms. Perfluorohexyloctane forms a monolayer at the air-liquid interface of the tear film which can be expected to reduce evaporation. The exact mechanism of action for MIEBO in DED is not known.

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 6b283c02-7df4-4c00-951b-555cddffe77c. Read the full official label on DailyMed.

Related medicines

Azithromycin Latanoprost Amoxicillin and Clavulanate Cephalexin Sulfamethoxazole and Trimethoprim Ofloxacin Timolol Cefdinir